drugset / Trial / NCT05289193

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

NCT05289193 ↗

Phase 2 Active not recruiting 28 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of this study is to find out whether neoadjuvant therapy with nivolumab and ipilimumab can kill melanoma tumors before surgery and prevent disease from coming back after surgery. This study also explores a new, experimental PET scan that images the immune system to see if it is related to treatment outcomes.

Timeline

Start
2022-03-11
Primary completion
2027-03-11
Completion
2027-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 3 mg/kg —
Subject Nivolumab Monoclonal antibody 1 mg/kg —

Indications